For the first time, the usage of the CADScor® System in a high prevalence cohort is described by M. Renker et al. This prospective randomized cohort was designed as technical study to confirm predicted sensitivity and specificity in a high prevalence patient group (not the intended patient group for the CADScor®System in clinical practice). Use of the CADScor®System allowed the identification of individuals with CAD in a high-prevalence cohort with a high sensitivity of 97.6% but with a lower specificity. The negative predictive value of 90.5% was within the predicted range for a high-prevalence cohort. The results were intended to be presented during the annual meeting of the German cardiac society and are published as poster abstract.
Acarix is a Swedish medical device company that innovates solutions for rapid AI-based rule out of Coronary Artery Disease (CAD). The CE approved and FDA DeNovo cleared Acarix CADScor®System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive and costly diagnostic procedures. The CADScor system calculates a patient-specific CAD-score non-invasively in less than10 minutes and can help rule out more than one third of patients with at least 96% certainty of not being sick (in a population with approx. 10% CAD prevalence). Acarix is listed on the Nasdaq First North Premier Growth Market (ticker: ACARIX). Redeye AB (+46 (0)8 121 576 90, firstname.lastname@example.org) is Certified Advisor of Acarix.